Insider Activity
Timothy M Mayleben, President and CEO at Esperion Therapeutics (ESPR), bought 5,000 shares of the company's common stock on Nov 6. At $36.98 per share, Mayleben paid a total of $184,900 for the new shares.
InvestorsKeyhole Trade Alert
